Moreover, several effective PXR agonists such as rifaximin (25, 32), curcumin (56), and Solomonterol A (29, 57–59), which have extended our understanding of the anti-inflammatory role of PXR, are expected to be leveraged as potential therapeutic drugs for clinical treatment of IBD. Here, NR1I2 is linked to inflammatory bowel disease.